Dyslipidemia (DL), defined by dysregulated levels of lipids in the bloodstream, is an ever-growing problem in modern society. In addition to those with congenital defects in lipid metabolism, the pervasive nature of high-fat and high-calorie diets in modern industrialized societies has led to a meteoric increase in its incidence. Patients who suffer from this condition subsequently are at a higher risk of developing other co-morbid conditions, most notably diabetes mellitus and coronary artery disease. This review explores another arguably lesser-known consequence of DL, pancreatitis, which is an inflammatory disease of the pancreas. The goal of this article is to review the intersection of these two conditions by briefly highlighting the proposed pathophysiology and exploring the impact of DL (specifically hypertriglyceridemia) on acute, acute recurrent, and chronic pancreatitis. This paper additionally examines the long-term risks of developing pancreatic cancer in patients with pancreatitis secondary to DL and presents unique clinical scenarios that result in DL-associated pancreatitis. Finally, we discuss potential treatment options for hypertriglyceridemia which can potentially mitigate the risk of DL-associated pancreatitis.
Pancreatic neuroendocrine neoplasms (PNENs) are a diverse group of rare tumor subtypes, representing less than 2% of all pancreatic tumors. Often detected late in the clinical course, they are associated with high rates of morbidity and mortality. Hereditary syndromes such as multiple endocrine neoplasia type-1 and von Hippel–Lindau are associated with the development of PNENs, although only a small portion of total tumors have a genetic basis. This review aims to explore the recent advances in laboratory diagnostics, imaging modalities, medical management, and surgical approaches to hormone-producing PNENs (including some common, less common, and some rare subtypes), with the goal of assisting physicians in the integration of evidence-based information into their practice.
Necrotizing enterocolitis is an overwhelming, catastrophic gastrointestinal disease largely affecting premature infants. The disease is manifested by exaggerated intestinal inflammation, which can progress to necrosis of the bowel and systemic sepsis. Prognosis is poor, with unacceptably high mortality. There is currently no known cure, with management focused on supportive measures, including bowel rest, gastric decompression, and antibiotic administration. Surgical intervention is required for cases unresponsive to medical management. In this review, we describe the determination of the need for surgical intervention, the surgical procedures commonly employed, and novel perioperative adjuncts being developed to improve outcomes.
Antibiotic prophylaxis minimizes the risk of infection, but overtreatment leads to antimicrobial resistance. Adult studies suggest antibiotic prophylaxis for elective cholecystectomy may not be needed. Our quality improvement project aimed to decrease prophylactic antibiotic use for elective cholecystectomies from 100% to ≤ 50% and maintain that rate for one year. Prior to initiation, the pre-operative orderset was modified, education was provided, and surgeon consensus was achieved. All patients undergoing elective minimally invasive (laparoscopic and robotic) cholecystectomy were included. Exclusion criteria included acute cholecystitis, immunocompromised state, or performance of a combined procedure. Compliance was measured by chart review, with feedback provided for noncompliance. The project was initiated January 2024. Data were collected for twelve months prior (1/23-12/23) and after initiation (1/24-12/24). The balancing measure was surgical site infection (SSI). Ninety patients met inclusion criteria (40 pre-protocol and 50 post-protocol). Median age at surgery was 16 years (IQR 14, 17.2). Seventy-seven (86%) patients were female. Prior to implementation, all patients (n=40) received prophylactic antibiotics. In the first three months post-implementation, 3/16 (19%) received antibiotic prophylaxis (due to inadequate communication with anesthesia providers). In the subsequent nine months, 0/34 (0%) received antibiotic prophylaxis. One (2.5%) patient in the pre-implementation group was noted to have an SSI requiring antibiotics vs. 3 (6%) patients in the post-implementation group (p=0.43). Use of prophylactic antibiotics for elective minimally invasive cholecystectomy decreased from 100% to 6% without significantly increasing the rate of SSI. Appropriately decreasing use of prophylactic antibiotics can improve antibiotic stewardship efforts. Level III.
The ability to provide ambulatory and mobile surgery services in rural and austere environments has seen tremendous growth in recent decades due to innovations in surgical techniques and equipment. These advances have been implemented in both civilian and military settings, increasing the capabilities of surgeons and surgical subspecialists across the globe. This review aims to briefly explore the history of ambulatory and mobile surgery and describe the recent efforts to make advancements in this field to improve global surgery opportunity and access, as well as to provide an overview of both military and civilian utilizations of mobile surgical teams and strategies.